Oruka Reports 61% Complete Skin Clearance at Week 16 in Trial
Oruka Therapeutics said 61% of patients receiving high-dose ORKA-001 achieved complete skin clearance at Week 16 in its Phase 2b psoriasis trial.
Oruka Therapeutics reported that 61% of patients receiving high-dose ORKA-001 achieved complete skin clearance at Week 16 in its Phase 2b trial.Key Highlights:Original SEC Filing: Oruka Therapeutics, Inc. [ ORKA ] - 8-K - Oct. 26, 2026This is an AI-powered summary. It may contain inaccuracies.
Cons…